Association of Selected Variants in Genes Involved in Cell Cycle and Apoptosis with Bladder Cancer Risk in North Indian Population

被引:23
作者
Gangwar, Ruchika [1 ]
Mittal, Rama Devi [1 ]
机构
[1] Sanjay Gandhi Postgrad Inst Med Sci, Dept Urol & Renal Transplantat, Lucknow 226014, Uttar Pradesh, India
关键词
URINARY-BLADDER; MDM2; POLYMORPHISMS; BREAST-CANCER; LUNG-CANCER; ONSET AGE; D1; CARCINOMA; ALLELE; P53; ESOPHAGEAL;
D O I
10.1089/dna.2009.0982
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Perturbations in the cell cycle and apoptotic genes have been implicated in human malignancies. Cell cycle (MDM2 and Cyclin D1) and apoptotic (Fas) genes that are differentially expressed in urinary bladder cancer (UBC) were investigated with the susceptibility to UBC in northern India. A total of 212 UBC patients and age-and sex-matched 250 controls were investigated for MDM2 G309T, Cyclin D1 G870A, and Fas A670G polymorphisms by polymerase chain reaction and restriction fragment length polymorphism. MDM2 309GG was at reduced risk for developing UBC when compared with TT genotype (p = 0.027; odds ratio, 0.55). GG genotype was also associated with reduced risk in nonmuscle invasive bladder cancer (NMIBC) and muscle invasive BC (p = 0.006 and p = 0.049). Cyclin D1 AA genotype was associated with high risk in NMIBC (intermediate risk) stage (p = 0.015; odds ratio, 4.55). MDM2-Cyclin D1 interaction revealed overall protective effect. The GG genotype of MDM2 also showed a protective effect and high recurrence-free survival in Bacillus Calmette-Guerin-treated NMIBC patients (log rank p = 0.008). MDM2 GG genotype had protective effect and MDM2T309G polymorphism had profound influence in Bacillus Calmette-Guerin-treated UBC patients in the North Indian population.
引用
收藏
页码:349 / 356
页数:8
相关论文
共 33 条
[1]  
BETTICHER DC, 1995, ONCOGENE, V11, P1005
[2]   Role of urothelial cells in BCG immunotherapy for superficial bladder cancer [J].
Bevers, RFM ;
Kurth, KH ;
Schamhart, DHJ .
BRITISH JOURNAL OF CANCER, 2004, 91 (04) :607-612
[3]   A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans [J].
Bond, GL ;
Hu, WW ;
Bond, EE ;
Robins, H ;
Lutzker, SG ;
Arva, NC ;
Bargonetti, J ;
Bartel, F ;
Taubert, H ;
Wuerl, P ;
Onel, K ;
Yip, L ;
Hwang, SJ ;
Strong, LC ;
Lozano, G ;
Levine, AJ .
CELL, 2004, 119 (05) :591-602
[4]   The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis [J].
Brown, DR ;
Thomas, CA ;
Deb, SP .
EMBO JOURNAL, 1998, 17 (09) :2513-2525
[5]   Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer [J].
Colombel, Marc ;
Soloway, Mark ;
Akaza, Hideyuki ;
Boehle, Andreas ;
Palou, Joan ;
Buckley, Roger ;
Lamm, Donald ;
Brausi, Maurizio ;
Witjes, J. Alfred ;
Persad, Raj .
EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (10) :618-626
[6]   A case-control study of cyclin D1 CCND1 870A→G polymorphism and bladder cancer [J].
Cortessis, VK ;
Siegmund, K ;
Xue, SY ;
Ross, RK ;
Yu, MC .
CARCINOGENESIS, 2003, 24 (10) :1645-1650
[7]   Functions of the MDM2 oncoprotein [J].
Freedman, DA ;
Wu, L ;
Levine, AJ .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (01) :96-107
[8]   Association between CCND1 G/A870 Polymorphism, Allele-Specific Amplification, Cyclin D1 Expression, and Survival in Esophageal and Lung Carcinoma [J].
Gupta, Vanita K. ;
Feber, Andrew ;
Xi, Liqiang ;
Pennathur, Arjun ;
Wu, Maoxin ;
Luketich, James D. ;
Godfrey, Tony E. .
CLINICAL CANCER RESEARCH, 2008, 14 (23) :7804-7812
[9]   MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma [J].
Hirata, Hiroshi ;
Hinoda, Yuji ;
Kikuno, Nobuyuki ;
Kawamoto, Ken ;
Suehiro, Yutaka ;
Tanaka, Yuichiro ;
Dahiya, Rajvir .
CLINICAL CANCER RESEARCH, 2007, 13 (14) :4123-4129
[10]   The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma [J].
Hong, Y ;
Miao, XP ;
Zhang, XM ;
Ding, F ;
Luo, AP ;
Guo, YL ;
Tan, W ;
Liu, ZH ;
Lin, DX .
CANCER RESEARCH, 2005, 65 (20) :9582-9587